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Background: In the present study, the influence of bacterial infection, lipopolysacharides (LPS) and hydroxyethyl
starch (HES) on platelet function in a parallel plate flow chamber were measured. Experiments were performed with
non-activated and protease-activating-receptor (PAR) 4 agonist activated platelets. Comparative measurements were
in vivo capillary bleeding time, platelet function analyzer and impedance aggregometry.
Results: PAR 4 agonist did not increase platelet adhesion of platelets from dogs with bacterial inflammation in the
flow chamber in contrast to platelets of healthy dogs. Except from impedance aggregometry with lower sensitivity
and specificity, PFA did not detect platelet dysfunctions in dogs with infection. In vitro addition of LPS or HES
significantly reduced platelet covered area after PAR-activation.
Conclusions: The flow chamber detects platelet dysfunctions in dogs with inflammatory diseases. In vitro addition
of LPS highlights the inhibiting effect of bacterial wall components on platelet function. Platelet dysfunction
induced by infection could possibly also be diagnosed after treatment of sepsis with colloids has commenced. The
flow chamber could be a useful tool to detect sepsis associated platelet dysfunction given that larger prospective
trials confirm these findings from a proof of concept study.
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Inflammation leads to activation of coagulation. In
addition, an exaggerated coagulability results in a further
augmentation of inflammation [1-3]. This mechanism is
based on the expression of tissue factor by mononuclear-
and endothelial cells, activated by pro-inflammatory cyto-
kines like interleukin 6 [4,5]. Furthermore, important natural
occurring anticoagulant pathways including antithrombin,
the protein C pathway and the tissue-factor-inhibitor path-
way can be inhibited as well as fibrinolysis [6,7]. This
leads to microvascular thrombosis and formation of intra-
vascular fibrin and finally to multiple organ failure [8,9].
Beside the general response, a localized response to in-
flammatory agents can be seen depending on the type of* Correspondence: theilmeier.gregor@mh-hannover.de
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reproduction in any medium, provided the ortissue, tissue environment, cell type and endothelial cell
response to inflammation [3,10,11]. Since organs differ in
these factors, it is likely that local coagulation and fibrin
deposition differ as well [8].
In bacterial inflammation, platelets are activated via
thrombin and pro-inflammatory mediators [3], causing
α-degranulation with an increase of P-Selectin expres-
sion on the platelet surface [12]. To assess platelet func-
tion, several functional assays have been suggested:
capillary bleeding time (CBT), platelet function analysis
(PFA) and impedance aggregometry (MultiplateW). PFA
is commonly used to monitor anti-platelet therapy and
as a screening tool for the von Willebrand disease [13].
Impedance aggregometry is used to monitor platelet
function in patients with inherited platelet dysfunctions
as well as aspirinW- and clopidogrel therapy to detect
non-responders or anti-platelet drug resistance respectively
[14-16]. Both tests are mainly based on platelet aggregationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not impedance aggregometry assesses platelet adhesion
and thrombus formation on platelet reactive surfaces. A
distinction of platelet adhesion to collagen versus
homotypic platelet-platelet interaction is not possible with
any of the available platelet function assays. However, an
exact diagnosis of disturbed thrombus formation on sur-
faces, especially in the setting of vessel wall injury and ex-
position of platelets to sub-endothelial structures like
collagen, is important to prevent thrombotic events in the
septic patient.
In a recent study we adapted methodological aspects
to assess interactions between canine platelets and a col-
lagen matrix in a flow chamber based adhesion assay
and defined parameters that allow reproducible examin-
ation of thrombus formation under flow conditions in
whole blood (Ferkau et al., in press). This system seems
to be ideal to study the influence of inflammation on
platelet adhesion and thrombus formation in compari-
son to conventional assays of platelet function such as
capillary bleeding time, automatic platelet function ana-
lyses using the PFA-100W and impedance aggregometry
using the MultiplateW impedance aggregometer.
The aim of the present study was to examine possible
influences of naturally occurring bacterial infection and
concomitant treatments on adhesion and thrombus for-
mation of canine platelets as assessed by the flow cham-
ber and to define the relationships between results




Blood samples of clinically healthy dogs (n = 16) and sam-
ples of dogs with bacterial inflammation (n = 8) were mea-
sured including platelet count and three conventional test
procedures of primary hemostasis (in vivo capillary bleed-
ing time, automatic platelet function analyzes using the
PFA-100W and impedance aggregometry using the
MultiplateW impedance aggregometer). Additional mea-
surements were performed with the flow chamber using
non-activated samples compared to samples with acti-
vated platelets using PAR 4 agonist. Supplementary
in vitro experiments examined the influence of LPS
(n = 5) and HES (n = 10) on the adhesion of platelets from
healthy dogs.
Animals
Dogs with bacterial inflammation were patients of the
Small Animal Clinic, University of Veterinary Medicine
Hannover. Included were patients presenting with a
local or systemic infectious disease caused by bacteria
(6 = abscess, 1 = peritonitis, 1 = hemorrhagic enteritis with
sepsis) and systemic symptoms (body temperature 37.6–39.6°C, median 38.8°C; heart rate 96–134 beats per min,
median 115 beats per min). Animals with infection had
blood cell counts with platelet counts of 99,000–
431,000/μL (median 269,000/μL), red blood cell counts
of 4.2–9.1 × 106/μL (median 5.9 × 106/μL), white
lood cell counts of 11.5–20.3 × 103/μL (median 15.6 ×
103/μL) and hematocrit values of 27.0–57.0% (median
39.6%). Blood samples were drawn before treatment
commenced.
Clinically healthy dogs used as controls were of differ-
ent age, gender and breed. Health status was confirmed
by a normal hematological and biochemical profile.
Healthy animals had normal blood cell counts with plate-
let counts of 107,000–399,000/μL (median 251,000 /μL),
red blood cell counts of 6.6–9.4 × 106/μL (median 7.7 ×
106/μL), white blood cell counts of 5.5–10.2 × 103/μL
(median 7.5 × 103/μL) and hematocrit values of 43.0–
62.0% (median 52.0%).
Experiments were performed in accordance with the
German Animal Welfare law and were approved by the
official animal health care officer of the university and
the local animal welfare authorities (Lower Saxony State
Office for Consumer Protection and Food Safety).
Blood sampling
Minimal pressure was deployed to raise the saphenous or
cephalic vein by an assistant to facilitate venipuncture and
blood draws. The samples were drawn using sterile dispos-
able needles (18 G) into several plastic tubes. 3.8-mL tubes
covered with buffered citrate solution (for PFA-100W,
0.129 mol/L trisodium citrate/citric acid buffer solution
pH 5.5, Sarstedt AG & Co, Nuembrecht, Germany), 4.5-mL
hirudin-coated tubes (MultiplateW, Verum Diagnostica
GmbH, Munich, Germany) and 1.3-mL EDTA tubes
(CBC) were used. Citrate anticoagulation (9 parts of
blood to 1 of part 0.11 M citrate solution) was used
for flow chamber studies. Blood and anticoagulant
were immediately mixed carefully. The samples were
stored at room temperature and used within 3 hours
after blood collection.
Hematological analyses (platelet count, red blood cell
count, hematocrit values) were measured automatically
using the hematology system ADVIA 120 (Siemens
Healthcare Diagnostics, Eschborn, Germany).
Capillary bleeding time
For capillary bleeding time awake dogs were brought
into lateral position. At the lateral side of the front toe
the hair was removed with a shaver and hyperemia was
induced (FinalgonW Crème, Boehringer Ingelheim,
Germany). Close to the edge of the skin of the pad two
punctures were placed with a sterile semi-automatic
blood lancet (Softclix II, Roche Diagnostics, Mannheim,
Germany). Before and during the measurement a steady
Ferkau et al. BMC Veterinary Research 2013, 9:112 Page 3 of 9
http://www.biomedcentral.com/1746-6148/9/112pressure of 70 mmHg was maintained with a blood pres-
sure cuff. Every 15 seconds blood drops were dabbed off
carefully until the bleeding stopped. The average bleed-
ing time was calculated as the mean time of the two
punctures [17].
Platelet function measurements with PFA 100W
Measurements with the platelet function analyzer PFA-
100W were performed according to the manufacturer’s
instructions using the collagen/adenosine-5′-diphos-
phate (CAPD) cartridge and the collagen/epinephrine
(CEPI) cartridge (Siemens Healthcare Diagnostics
GmbH, Eschborn, Germany). The blood sample was
filled into the cartridge and sucked under a constant
vacuum of 40 mmHg through a capillary membrane.
The membranes central aperture is coated with different
agonists that induce platelet activation. “Closure time” is
defined as the time, which is required to completely
close this aperture (in sec, maximal testing time
300 sec). The “total volume” (in μL) describes the
amount of blood needed to achieve closure.
Platelet aggregation in MultiplateW impedance
aggregometer
Impedance aggregometry was performed with the
MultiplateW impedance aggregometer according to the
manufacturers recommendations.
300 μL blood were mixed gently with 300 μL 0.9%
NaCl and incubated for 3 minutes at 37°C before 20 μL
of the respective agonist solution were added. Thrombus
formation was followed for 12 minutes. MultiplateW de-
tects an increase in electrical impedance caused by
platelets attaching to the surface of the sensor wires. Re-
sults are converted by the built-in algorithm into arbi-
trary “Aggregation Units” (AU). The “Area under the
curve” (AUC in AU*min) is an integrated measure of the
velocity (AU/min) of aggregation and is reported to re-
flect maximal aggregation. Agonist concentrations were
5 μg/mL collagen, 10 μmol/L adenosine diphosphate
and 1 mmol/L arachidonic acid [18]. Instruments and
reagents were purchased from Verum Diagnostica
GmbH (Munich, Germany).
Measurements in the flow chamber
Substrate coating
To prepare a canine collagen solution 10 mg of lyophi-
lized canine collagen (YO Proteins AB, Huddinge,
Sweden) were diluted in 10 mL of 2.5 mol/L acetic acid
and kept on a tumbler for 5 hours at 4°C. Subsequently
the remaining sediment was resolved by a homogenizer.
The stock solution was diluted with Dulbecco’s phos-
phate buffered saline (DPBS, Lonza, Cologne, Germany)
to achieve a final concentration of 200 μg/mL canine
collagen.The substrate is a plastic chip which can be coated
with matrix proteins like collagen. Before coating sub-
strates were washed in 70% ethanol and in DPBS. 125
μL of the collagen solution was placed in a Petri dish
and the substrate carefully placed on it. The substrate
was incubated at least 2 hours in the refrigerator. Before
use the substrate was gently washed in DPBS to remove
excess collagen solution.
Platelet staining
Platelets in whole blood were stained with the fluores-
cent dye Dihexylcarbocyanine Iodide (DiOC6, Invitrogen,
Frankfurt, Germany) at a final concentration of 1 μmol/L.
To achieve this, 10 μL of the stock solution (prepared to
manufacturer’s instructions) were added to 1 mL of
citrated blood and incubated for 30 minutes under exclu-
sion of light. The success of the staining was controlled
microscopically in a native preparation.
PAR 4 agonist preparation
The stock solution of the agonist PAR 4 was prepared by
dissolving the lyophilized reagent in 1 mL purified water
to achieve a concentration of 20 mmol/L. Aliquots of
50 μL were produced and according to recommendations
of the manufacturer stored at −20°C for a maximum of
4 weeks.
Flow chamber
The flow chamber based adhesion assay using citrated
whole blood was performed in a disposable biochip per-
fusion chamber (VenaEC™, Cellix Ltd., Dublin, Ireland).
The biochip perfusion chamber only requires approxi-
mately 100 μL of blood for a 3 minute experiment at a
wall shear stress of 14 dynes/cm2. The biochip was de-
veloped for human samples and mimics human capilla-
ries. The biochip was placed in DPBS for at least
30 minutes according to recommendations of the manu-
facturer to soak the silicone membranes of the channel
to avoid leakiness of the channel when mounting it on
the substrate. Each biochip consists of 2 parallel chan-
nels (flow chamber dimensions: 20 mm length × 600 μm
width × 120 μm depth) and is placed on the associated
collagen coated substrate. The cannels are measured
consecutively.
To accomplish a wall shear stress of 14 dynes/cm2
during the experiment, a precision microfluidic syringe
pump (Mirus™ 2.0 Nanopump, Cellix Ltd., Dublin,
Ireland) was used which was controlled by a personal
computer in combination with the recommended soft-
ware (FlowAssay™ Software, Cellix Ltd., Dublin, Ireland).
The pump was employed in withdrawal mode to
generate a flow that was calculated to achieve the preset
shear rate.
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At the beginning of the experiment, the biochip was
mounted on the collagen coated substrate and placed on
the stage of an inverted epifluorescence microscope
(Olympus, Hamburg, Germany) equipped with a CCD
camera (Retiga EXi, Qimaging, Surrey, Canada). The
measurement channel was rinsed with Hank’s Balanced
Salt Solution (HBSS, Lonza, Cologne, Germany). Subse-
quently stained whole blood was perfused through the
channel for 3 minutes. Afterwards the channel was
washed out with HBSS for 1 minute before 10 pic-
tures of 115,6 mm2 (500 × 500 frames) each on the
entire length of the passage were recorded at 40-fold
magnification. Pictures were recorded still under flow
conditions.
To achieve platelet activation 100 μL samples of whole
stained blood were incubated with 10 and 20 μL PAR 4
agonist to achieve a final concentration of 1.8 mmol/L.
Platelets were incubated for 10 minutes at room
temperature and immediately perfused into the biochip.
Measurement parameters
Areas of interest (parameter threshold) were defined
manually in every single picture to detect all districts
covered by fluorescing platelets. For one channel 10 cor-
responding pictures were measured. Platelet covered
area and average thrombus sizes were calculated in every
picture and a mean was calculated for each parameter
per channel.
Software "groß" ImageJ 1.38× (National Institutes of
Health, USA) was used to measure the total area covered
by adhering platelets (μm2) and the average size of indi-
vidual thrombi (μm2). The detection limit was set to >
4 μm2 (corresponding to at least 2 platelets).
In vitro experiments
To investigate the influence of LPS, blood samples from
healthy dogs were incubated for 30 minutes with 0.3 ng/mL
LPS (E. coli, serotype 0111:B4, Sigma Aldrich, Taufkirchen,
Germany).
The influence of HES on platelet function was investi-
gated by incubating 100 μL blood samples of healthy
dogs with 12 μL of HES 6% (VitafusalW 6%, 130 kDA,
Serumwerk Bernburg AG, Bernburg, Germany) for
10 minutes prior to perfusion experiments. The dose
was chosen based on the recommended dose for patients
receiving a dose of 10 mL HES per kg body weight.
Statistical analysis
Data were tested for normal distribution using the
Kolmogorov-Smirnov test. Data were normally distri-
buted for all data families except for the HES study. Sta-
tistical significance was thus assessed with t-tests for
normally distributed data (paired and unpaired t-tests)and with non-parametric tests for the non-normally dis-
tributed data of HES co-incubation (Wilcoxon test for
paired data, Mann–Whitney U test for unpaired data).
These data are presented as medians and 95% CI and
graphically depicted as box plots. Areas under the re-
ceiver operating characteristics curve (AUC of ROC)
were compared as described by DeLong [19]. The com-
pared AUCs contained non-nested data [20]. Two-sided
values of P < 0.05 were considered as significant.
Results
Hematocrit and red blood cell count
Hematocrit values and red blood cell counts in dogs
with inflammation were significantly decreased in com-
parison to healthy dogs (P < 0.05, unpaired t-test).
Capillary bleeding time
Capillary bleeding time (25/75% percentile; healthy dogs
58–92 sec, median 71 sec vs. dogs with inflammation
37–123; median 84 sec) in healthy dogs and dogs with
inflammation showed no significant difference (P > 0.05,
unpaired t-test).
Platelet function analyzer
While a trend was seen with respect to a reduced
collagen-mediated activatability did the PFA parameters
“closure time” and “total volume” not show significant
differences when comparing healthy dogs and dogs with
infection (Figure 1, closure time; total volume COL/
ADP: 252; 231/275 μL vs. 286; 232/360 μL; total volume
COL/EPI: 392; 279/737 μL vs. 638; 257/871 μL; P > 0.05,
unpaired t-test).
Impedance aggregometry
In contrast, in impedance aggregometry platelet aggrega-
tion of dogs with infection was significantly decreased in
comparison to healthy dogs when using the agonist colla-
gen (P < 0.01, U-test) (Figure 2) but not with ADP. (AUC
values of arachidonic acid: 1686; 1004/2874 AU*min vs.
867; 266/3919 AU*min).
Results of flow chamber measurements
Platelet adhesion to collagen and thrombus formation in
the flow chamber did not show significant differences in
platelet covered area and average size of platelet covered
areas of non-activated platelets of healthy dogs and dogs
with infection (P > 0.05, unpaired t-test). Platelet covered
area (P < 0.01, paired t-test) and average size of platelet
covered areas (P < 0.01, paired t-test) of healthy dogs in-
creased significantly after platelet activation with PAR 4
agonist. In contrast, in dogs with infection neither plate-
let covered area nor average size of platelet covered
areas increased after platelet activation with PAR 4
agonist (P > 0.05, paired t-test). After platelet activation
Figure 1 Platelet dysfunction in dogs with infection as assessed
in the platelet function analyzer (PFA). Closure time of dogs with
bacterial inflammation (n = 8) in comparison to clinically healthy
dogs (n = 16) measured in the platelet function analyzer with the
cartridge types collagen/adenosine-5′-diphosphate (COL/ADP) and
collagen/epinephrine (COL/EPI) (mean ± SD; P > 0.05,
unpaired t-test).
Figure 3 Platelet dysfunction in dogs with infection as assessed
in the flow chamber. Platelet covered area a) and average size of
platelet covered areas b) of dogs with bacterial inflammation (n = 8)
in comparison to clinically healthy dogs (n = 16) investigated in the
flow chamber under standardized conditions (canine collagen
200 μg/mL, wall shear stress 14 dynes/cm2) in non-activated and
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of platelet covered areas in dogs with infection was
significantly decreased in comparison to healthy dogs
(unpaired t-test, P < 0.05) (Figure 3).Figure 2 Platelet dysfunction in dogs with infection as assessed
in impedance aggregometry. Area under the curve (AU*min) of
dogs with bacterial inflammation (n = 8) in comparison to clinically
healthy dogs (n = 16) measured in the impedance aggregometry
with the agonists collagen and ADP (mean ± SD; * = P < 0.05,
unpaired t-test).
PAR 4 agonist activated platelets (mean ± SD; * = P < 0.05; paired
t-test, # = P < 0.05; unpaired t-test).Results of areas under the ROC curve
We next asked, which of the examined platelet function
parameters would detect infection-associated platelet
dysfunction with the highest sensitivity. Areas under the
ROC curve were 0.54 (CBT), 0.66 (PFA COL/ADP) and
0.57 (MultiplateW impedance aggregometry; agonist col-
lagen). For flow chamber studies area under the ROC
curve was 0.91 for average size of platelet covered area
after platelet activation with PAR 4 agonist.
The AUC of average size of platelet covered area was
significantly higher than the AUC of MultiplateW imped-
ance aggregometry (P < 0.05, DeLong test) (Figure 4).
The sensitivities and specificities of the tests that were
compared in the ROC analysis are displayed in Table 1.
In vitro addition of LPS
Bacterial wall components like LPS have been shown to
induce sepsis-associated platelet dysfunction. To assess
if LPS-induced platelet dysfunction can be detected in
the flow chamber we conducted additional in vitro stu-
dies. After in vitro addition of LPS to examine the
Figure 4 Receiver operating curve analysis of different assays
of platelet function. Comparison of areas under the receiver
operating characteristics curve (AUC of ROC) of CBT, PFA COL/ADP,
impedance aggregometry (agonist collagen) and the parameter
average size of platelet covered area after activation with PAR 4
agonist. Two-sided values of P < 0.05 were considered as significant.
Figure 5 LPS-induced platelet dysfunction as assessed by the
flow chamber. Average size of platelet covered areas of samples
treated with LPS (n = 5) in comparison to non-LPS-treated samples
investigated in the flow chamber under standardized conditions
(canine collagen 200 μg/mL, wall shear stress 14 dynes/cm2) in non-
activated and PAR 4 agonist activated platelets (mean ± SD; * =
P < 0.05, paired t-test; # = P < 0.05, unpaired t-test).
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of platelet covered areas (P < 0.05, unpaired t-test) of
PAR 4 agonist activated platelets were significantly lower
in activated LPS treated samples than in the activated
non-treated control. As in the control, average size of
platelet covered areas (P < 0.05, paired t-test) increased
significantly after platelet activation with PAR 4 agonist
in LPS treated samples (Figure 5).
In vitro additon of HES
Therapy of infection with systemic symptoms mainly re-
lies on antibiotic treatment and replacement of volume
depletion. Since colloids, i.e. starch has been demon-
strated to induce platelet dysfunctions, we tested in vitro
if the flow chamber would be affected by clinically used
treatment strategies. In vitro addition of HES caused a
significantly decreased average size of platelet covered
areas (P < 0.05, Mann–Whitney U test) in comparison to
the non-treated control. As in the control, plateletTable 1 Sensitivities and specificities of tests compared in
the ROC analyses
Parameter Criterion AUC Sens Spez
FC Size + PAR ≤ 30,76 0,914 87,5 87,5
MP Coll AUC > 2713 0,570 50,0 87,5
PFA Coll/ADP VZ > 81 0,663 50,0 100,0
CBT > 97,5 0,542 50,0 92,9
Flow chamber derived parameters could deliver means to improve sensitivity
and specificity of tests batteries for the detection of relevant platelet
dysfunction compared to the use of established methods to assess
platelet function.activation with PAR 4 agonist in the HES treated sam-
ples increased average size of platelet covered areas
(P < 0.05, Wilcoxon test). Average size of platelet covered
areas after activation was significantly lower in compari-
son to average size of platelet covered areas after activa-
tion in the non-treated control (P < 0.05, Mann–Whitney
U test) (Figure 6).Discussion
The present study demonstrates that conventional assays
of platelet function provide limited sensitivity to detect
platelet dysfunctions in dogs associated with infection.
In contrast, the flow chamber detects infection associ-
ated platelet dysfunction in dogs, since platelet activation
in response to PAR 4 agonist was disturbed in these ani-
mals. In vitro, addition of LPS highlights the inhibiting
effect of LPS on platelet function. Platelet dysfunctions,
which are associated with the substitution of HES, are as
well represented in the flow chamber.
In contrast to other platelet function assays, capillary
bleeding time and platelet function analyzer did not de-
tect significant differences in healthy dogs and dogs with
infection. This was also confirmed by the calculated
AUCs of the ROC. The various assays for platelet func-
tion used in this study are known to detect different as-
pects of platelet function. Bleeding time is a global
coagulation parameter, closely resembling the clinical
setting but it is regretfully not very specific or sensitive
for any bleeding disorder, because results depend on fac-
tors of the animals (thickness of the skin, blood pressure,
vessel-wall structure) and on technical factors (intensity
Figure 6 HES-induced platelet dysfunction as assessed in the
flow chamber. Average size of platelet covered areas of samples
treated with HES (n = 10) in comparison to non-HES-treated samples
in the flow chamber under standardized conditions (canine collagen
200 μg/mL, wall shear stress 14 dynes/cm2) in non-activated and
PAR 4 agonist activated platelets (median ± min/max; * = P < 0.05,
Mann–Whitney U test; # = P < 0.05, Wilcoxon test).
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on breeds and individuals [21,22].
As already mentioned, platelet function analyzer is
normally used to detect anti-coagulant substances in pa-
tients. Platelet function is measured under non-
physiological, high wall shear stress conditions from 150
up to 190 dynes/cm2 [23,24]. It is known that already a
wall shear stress from up to 50 dynes/cm2 leads to
changes in platelet morphology, granule secretion and
platelet aggregation [25]. Changes in platelet function
caused by a high wall shear stress may mask a mildly
disturbed platelet function induced by infection. PFA
does however incorporate a platelet-wall interaction
component into the analysis. In addition, platelet count
and hematocrit values have to be considered since both
values influence the test result of the platelet function
analyzer [26,27].
The AUC of the ROC of the MultiplateW impedance
aggregometer, at least using the agonist collagen, indi-
cated that the MultiplateW impedance aggregometer
detected platelet dysfunction induced by infection. In
contrast to the platelet function analyzer, impedance
aggregometry measures platelet aggregation in response
to platelet agonists under conditions of low shear stress
but without a distinct vessel wall component. For the ex-
periment, blood samples are diluted in normal saline
[18]. Nevertheless, platelets of dogs with infection
showed a significantly attenuated aggregation response
to collagen. This result indicates reduced platelet func-
tion and a reduced platelet response to this matrix pro-
tein in dogs with infection. Interestingly was the
activation in response to ADP not affected.In our flow chamber studies, platelet covered area and
average size of platelet covered areas in dogs with infec-
tion and healthy dogs did not show significant diffe-
rences at baseline. However, platelets of dogs with
infection failed to respond to platelet activation with
PAR 4 agonist. That is particularly interesting since in
impedance aggregometry the TRAP test is considered as
a positive control that remains unaffected by most dys-
functional states of platelets.
In inflammation, circulating mononuclear cells express
tissue factor, which sets off the plasmatic coagulation
cascade and ultimately generates thrombin from pro-
thrombin. Thrombin is a potent agonist to activate
platelets via protease activated receptors [28] and leads
to platelet shape change, granule secretion and platelet
aggregation [29-31]. An increased expression of P-
selectin was detected on the platelet surface of dogs with
inflammatory diseases, which indicates an in vivo activa-
tion and degranulation [12]. In other studies “platelet ex-
haustion” was detected in dogs with pancreatitis [32].
This exhaustion is viewed as the consequence of
submaximal activation after platelet exposure to throm-
bin in vivo secondary to the generation of immune com-
plexes or contact to damaged endothelium [33].
Platelet exhaustion can also be the cause for the lack
of responsiveness to PAR 4 agonist activation of platelets
in dogs with infection. Changes in receptor expression
on the platelet surface are probably not the reason for
missing platelet activation, as receptor expression and
adhesion molecules remain unchanged in human pa-
tients with sepsis [34]. Nevertheless, does the missing re-
sponse of platelets to PAR 4 agonist activation allow
discrimination between healthy dogs and dogs with in-
fection in the flow chamber.
This is also demonstrated by the AUCs of the ROC of
the flow chamber parameters, since both platelet cov-
ered area AUC of the ROC and average size of platelet
covered area AUC of the ROC for the PAR 4 agonist
condition provide very good prediction of the presence
of platelet dysfunction secondary to infection.
The comparison of the AUC of ROC of MultiplateW
impedance aggregometry and flow chamber parameters
after platelet activation with PAR 4 agonist indicates a
trend to an improved sensitivity of the flow chamber,
probably due to a better representation of the in vivo
situation in the flow chamber. This trend is also corrob-
orated by the higher specificity and sensitivity of flow
chamber parameters compared to the standard tools to
assess platelet function.
Hematocrit values were significantly decreased in dogs
with infection. To eliminate the possibility that hematocrit
values affect platelet response to agonists and to highlight
the situation of infection, blood samples of healthy dogs
with normal hematocrit values were incubated with LPS
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nificant difference between the control and LPS treated
samples under resting conditions. Interestingly, platelet
activation with PAR 4 agonist still increased average size
of platelet covered area. In comparison to the non-LPS-
treated control average size of platelet covered area after
platelet activation with PAR 4 agonist in LPS treated sam-
ples was significantly decreased but responsiveness was
not completely abolished. We chose LPS because an in-
hibitory effect of LPS on platelet aggregation has previ-
ously been described by Saba et al. [35] in platelet rich
plasma. Most of our patients presented with abscesses that
are frequently caused by staphylococci and not by gram-
negative E. coli. We used LPS as one example for bacterial
wall components. Similar studies with lipoteichoic acid or
other bacterial activators would likely yield comparable ef-
fects. This inhibitory effect of LPS on platelet responsive-
ness may have been induced by direct binding of LPS to
the platelet surface [36]. LPS altered platelet responses to
agonists in a study of Nystrom et al. [37], but it has to be
considered that the effect of LPS on platelets is dose
dependent [38]. In the present study we used LPS at a
concentration of 0.3 ng/mL, which is a concentration that
has been observed in patients with sepsis [39]. Since
Nystrom et al. [37] used a much higher concentration of
80 mg/L, which probably does not reflect the situation
in vivo, it is not surprising that results of the two studies
differ.
Another potential reason for disturbed platelet respon-
siveness to thrombin activation could be infusion therapy
in septic patients. In order to investigate if the first line
therapy would affect the performance of the flow chamber
experiments, we substituted HES in blood of healthy ani-
mals. In vitro substitution of HES to blood samples of
clinically healthy dogs in an equivalent dose to 10 mL/kg
body weight decreased average size of platelet covered
areas. Platelet activation with PAR 4 agonist increased
average size of platelet covered areas in HES treated sam-
ples and in the control, but in comparison to the control
average size of platelet covered area in HES treated sam-
ples was significantly reduced. The resulting picture does
however not resemble the one caused by clinically signifi-
cant infection. An inhibiting effect of HES on platelet
function and blood coagulation has previously been de-
scribed. For example after substitution of HES in dogs a
prolonged platelet closure time in the PFA was seen, but
only at a dose of 20 mL/kg body weight [40,41]. A dose
dependent effect of HES was described in humans by Liu
et al. [42], who also detected notable effects on platelet
function after greater than 20% dilution with HES. A pos-
sible inhibitory mechanism of HES on platelet function is
an unspecific coating of platelets by HES macromolecules
[43], which may decrease the availability of the platelet
glycoprotein IIb-IIIa complex [44]. Our results indicate aninhibiting effect of HES on platelet function, even at a low
concentration of substitution. In contrast, a low dose of
HES does not affect the possibility of platelet activation.
Taken together, substitution of HES in a low dose prob-
ably only leads to a slight hemodilution, but may worsen
an already altered hemostasis in patients with inflamma-
tion. The effect of HES infusions alone does however not
explain the total lack of the platelet response seen in dogs
with infection. HES therapy would however not mask the
diagnosis of sepsis associated platelet dysfunction and ren-
der flow chamber studies to secure this diagnosis useful.
Conclusion
The flow chamber was able to detect infection associated
platelet dysfunction in dogs, by unmasking a lack of a
platelet response to PAR 4 agonist. Our small proof of
principle study should be followed up by a larger
prospective study that addresses the question if platelet
dysfunction is useful to detect infection, if infection-
associated platelet dysfunction detected by the flow
chamber is associated with clinically relevant bleeding
and if flow chamber parameters are indeed superior to
conventional parameters like PFA and MultiplateW to
detect this dysfunction.
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